| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
136,480,000 |
| Market
Cap: |
4.48(B) |
| Last
Volume: |
503,160 |
Avg
Vol: |
501,762 |
| 52
Week Range: |
$26.23 - $39.94 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Perrigo is a provider of over-the-counter health and wellness solutions that can be self-managed. Co.'s segments are as follows: Consumer Self-Care Americas, which is focused primarily on the sale of self-care products in categories including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements; Consumer Self-Care International, which develops, manufactures, markets, and distributes European consumer self-care brands in the upper respiratory, pain and sleep-aids, digestive health, vitamins, minerals and supplements; and Prescription Pharmaceuticals, which develops, manufactures, and markets a portfolio of generic prescription drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Farrington Thomas |
Senior VP and CIO |
• – – |
2012-11-29 |
4 |
S |
$103.16 |
$63,238 |
D/D |
(613) |
1,040 |
|
- |
|
| Farrington Thomas |
Senior VP and CIO |
• – – |
2012-11-29 |
4 |
OE |
$20.50 |
$20,049 |
D/D |
978 |
1,653 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2012-11-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,749 |
603,082 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2012-11-26 |
4 |
GD |
$0.00 |
$0 |
I/I |
373 |
604,831 |
|
- |
|
| Gibbons David T |
Director |
– • – |
2012-11-26 |
4 |
S |
$102.18 |
$5,194,204 |
D/D |
(50,778) |
11,625 |
|
- |
|
| Gibbons David T |
Director |
– • – |
2012-11-26 |
4 |
OE |
$18.18 |
$796,410 |
D/D |
30,778 |
13,849 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2012-11-26 |
4 |
AS |
$103.28 |
$282,994 |
D/D |
(2,740) |
18,465 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2012-11-26 |
4 |
OE |
$30.06 |
$82,364 |
D/D |
2,740 |
21,205 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2012-11-21 |
4 |
GD |
$0.00 |
$0 |
I/I |
648 |
605,204 |
|
- |
|
| Kingma Todd W |
Executive VP, General Counsel |
• – – |
2012-11-21 |
4 |
GD |
$0.00 |
$0 |
I/I |
650 |
1,736 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2012-11-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,793 |
605,852 |
|
- |
|
| Papa Joseph C |
President and CEOChairman |
• • – |
2012-11-15 |
4 |
AS |
$100.75 |
$1,511,747 |
D/D |
(15,000) |
115,645 |
|
- |
|
| Papa Joseph C |
President and CEOChairman |
• • – |
2012-11-15 |
4 |
OE |
$30.06 |
$450,900 |
D/D |
15,000 |
130,645 |
|
- |
|
| Brlas Laurie |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
18,181 |
|
- |
|
| Fouse Jacqualyn A |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
883 |
|
- |
|
| Hoffing Ellen Randi |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
6,051 |
|
- |
|
| Cohen Gary M |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
18,610 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2012-11-14 |
4 |
GD |
$0.00 |
$0 |
I/I |
4,195 |
1,045,145 |
|
- |
|
| Jandernoa Michael J |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
1,623 |
|
- |
|
| Zilberfarb Ben-Zion |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
5,343 |
|
- |
|
| Gibbons David T |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
31,625 |
|
- |
|
| Morris Herman Jr |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
18,848 |
|
- |
|
| Kunkle Gary K Jr |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
22,654 |
|
- |
|
| Gottfried Ran |
Director |
– • – |
2012-11-14 |
4 |
A |
$0.00 |
$0 |
D/D |
868 |
11,609 |
|
- |
|
| Kochan Sharon |
Executive VP U.S. Generics |
• – – |
2012-11-14 |
4 |
A |
$104.11 |
$237,371 |
D/D |
2,280 |
5,492 |
|
- |
|
1400 Records found
|
|
Page 10 of 56 |
|
|
0.27 (0.82%) 
